AGADA is a contract research organization (CRO) providing specialized services to pharmaceutical and biotech companies. Unlike most CROs, AGADA provides services in niche areas of research that require further standardization. Our mission is to facilitate and accelerate drug development for rare diseases, serving an internation clientele. Key to accomplishing this mission is training and retaining a highly skilled workforce in Nova Scotia. We offer both preclinical drug efficacy studies and clinical (human) trial drug development support services. AGADA has performed over 100 drug efficacy studies in murine models of muscular dystrophy and has supported >50 Phase I/II clinical efficacy studies (Duchene, Becker, ALS, DM1).
